M. BEKSAÇ Et Al. , "Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma," 49th Annual Meeting of the American-Society-of-Hematology , vol.110, Georgia, United States Of America, 2007
BEKSAÇ, M. Et Al. 2007. Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma. 49th Annual Meeting of the American-Society-of-Hematology , (Georgia, United States Of America).
BEKSAÇ, M., Soydan, E., ÖZKOCAMAN, V., TOPÇUOĞLU, P., Evranos, B., Kizil, M., ... Bilgin, A. U.(2007). Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma . 49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America
BEKSAÇ, MERAL Et Al. "Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma," 49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 2007
BEKSAÇ, MERAL Et Al. "Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma." 49th Annual Meeting of the American-Society-of-Hematology , Georgia, United States Of America, 2007
BEKSAÇ, M. Et Al. (2007) . "Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma." 49th Annual Meeting of the American-Society-of-Hematology , Georgia, United States Of America.
@conferencepaper{conferencepaper, author={MERAL BEKSAÇ Et Al. }, title={Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma}, congress name={49th Annual Meeting of the American-Society-of-Hematology}, city={Georgia}, country={United States Of America}, year={2007}}